title: Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma.
abstract: Ramucirumab, a fully humanized monoclonal antibody directed against vascular endothelial growth factor receptor 2, is the first targeted agent to have demonstrated an improvement in survival, as a single agent or in combination, in a molecularly unselected population in gastro-oesophageal cancer. Now that second-line treatment is routinely considered for patients with advanced gastro-oesophageal cancer, ramucirumab, with its favourable toxicity profile compared with cytotoxic treatment, provides a valuable additional treatment option.
authors.affiliation: Royal Marsden Hospital, Gastrointestinal Oncology Unit, Sutton, Surrey, UK.
authors.forename: Kate
authors.initials: K
authors.lastname: Young
authors.affiliation: Royal Marsden Hospital, Gastrointestinal Oncology Unit, Sutton, Surrey, UK.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Smyth
authors.affiliation: Royal Marsden Hospital, Gastrointestinal Oncology Unit, Down's Road, Sutton, Surrey SM2 5PT, UK.
authors.forename: Ian
authors.initials: I
authors.lastname: Chau
keywords: angiogenesis; gastric cancer; gastro-oesophageal cancer; ramucirumab; vascular endothelial growth factor; vascular endothelial growth factor receptor 2